Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 840-851

  Cory, Theodore J ^a,b   Birket, Susan E ^a   Murphy, Brian S ^a   Mattingly, Cynthia ^a   Breslow Deckman, Jessica M ^a   Feola, David J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bacterial infections; Lung inflammation; P. Aeruginosa

Indexed keywords

ARGINASE; AZITHROMYCIN; FIBRONECTIN; GELATINASE B; LIPOPOLYSACCHARIDE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL FUNCTION; CELL INTERACTION; CELL STIMULATION; CELL VIABILITY; COCULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; HOMEOSTASIS; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; UPREGULATION;

ANIMALS; AZITHROMYCIN; CELL LINE; COCULTURE TECHNIQUES; FIBROBLASTS; FIBRONECTINS; IMMUNOLOGIC FACTORS; MACROPHAGES; MICE; PSEUDOMONAS AERUGINOSA;

EID: 84875269923     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks476     Document Type: Article

References (39)

1. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
2. Kitowska K, Zakrzewicz D, Konigshoff M et al. Functional role and species-specific contribution of arginases in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L34-45.
3. Liu Y, Van Ginderachter JA, Brys L et al. Nitric oxide-independent CTL suppression during tumor progression: association with arginaseproducing (M2) myeloid cells. J Immunol 2003; 170: 5064-74.
4. Heine UI, Munoz EF, Flanders KC et al. Colocalization of TGF-beta 1 and collagen I and III, fibronectin and glycosaminoglycans during lung branching morphogenesis. Development 1990; 109: 29-36.
5. Vaday GG, Schor H, Rahat MA et al. Transforming growth factor-b suppresses tumor necrosis factor a-induced matrix metalloproteinase-9 expression in monocytes. J Leukoc Biol 2001; 69: 613-21.
6. Sheppard D. Transforming growth factor b: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 2006; 3: 413-7.
7. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-56.
8. Wolter J, Seeney S, Bell S et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-6.
9. Equi A, Balfour-Lynn IA, Bush A et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-84.
10. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 41 Suppl B: 47-50.
11. Verleden GM, Vanaudenaerde BM, Dupont LJ et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patientswith bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-70.
12. Meyer M, Huaux F, Gavilanes X et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009; 41: 590-602.
13. Murphy BS, Sundareshan V, Cory TJ et al. Azithromycin alters macrophage phenotype. J Antimicrob Chemother 2008; 61: 554-60.
14. Feola DJ, Garvy BA, Cory TJ et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob Agents Chemother 2010; 54: 2437-47.
15. Jainchill JL, Aaronson SA, Todaro GJ. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 1969; 4: 549-53.
16. Ralph P, Nakoinz I. Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line. Nature 1975; 257: 393-4.
17. van Heeckeren AM, Schluchter MD. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 2002; 36: 291-312.
18. Nacucchio MC, Cerquetti MC, Meiss RP et al. Short communication. Role of agar beads in the pathogenicity of Pseudomonas aeruginosa in the rat respiratory tract. Pediatr Res 1984; 18: 295-6.
19. Corraliza IM, Campo ML, Soler G et al. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994; 174: 231-5.
20. Matteson DS, Soloway AH, Tomlinson DW et al. Synthesis and biological evaluation of water-soluble 2-boronoethylthio compounds. J Med Chem 1964; 7: 640-3.
21. Busnel O, Carreaux F, Carboni B et al. Synthesis and evaluation of new v-borono-a-amino acids as rat liver arginase inhibitors. Bioorg Med Chem 2005; 13: 2373-9.
22. Lee M, Villegas-Estrada A, Celenza G et al. Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des 2007; 70: 371-82.
23. Corbel M, Belleguic C, Boichot E et al. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 2002; 18: 51-61.
24. Christ M, McCartney-Francis NL, Kulkarni AB et al. Immunedysregulation in TGF-beta 1-deficient mice. J Immunol 1994; 153: 1936-46.
25. Pulichino AM, Wang IM, Caron A et al. Identification of transforming growth factor b1-driven genetic programs of acute lung fibrosis. Am J Respir Cell Mol Biol 2008; 39: 324-36.
26. Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29 Suppl: S32-6.
27. Harris WT, Muhlebach MS, Oster RA et al. Plasma TGF-b1 in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy. Pediatr Pulmonol 2011; 46: 688-95.
28. Brazova J, Sismova K, Vavrova V et al. Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin Immunol 2006; 121: 350-7.
29. Koth LL, Alex B, Hawgood S et al. Integrin b6 mediates phospholipid and collectin homeostasis by activation of latent TGF-b1. Am J Respir Cell Mol Biol 2007; 37: 651-9.
30. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-29.
31. Lee CG, Homer RJ, Zhu Z et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor b1. J Exp Med 2001; 194: 809-21.
32. Marom B, Rahat MA, Lahat N et al. Native and fragmented fibronectin oppositely modulate monocyte secretion of MMP-9. J Leukoc Biol 2007; 81: 1466-76.
33. Nichols D, Chmiel J, Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol 2008; 34: 146-62.
34. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163-76.
35. Suki B, Bates JH. Extracellular matrix mechanics in lung parenchymal diseases. Respir Physiol Neurobiol 2008; 163: 33-43.
36. Hoffmann N, Lee B, Hentzer M et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr2/2 mice. Antimicrob Agents Chemother 2007; 51: 3677-87.
37. Kohler T, Perron GG, Buckling A et al. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog 2010; 6: e1000883.
38. Cosgrove S, Chotirmall SH, Greene CM et al. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/ Toll-like receptor pathway. J Biol Chem 2011; 286: 7692-704.
39. Murphy BS, Bush HM, Sundareshan V et al. Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros 2010; 9: 314-22.